Partner Therapeutics
Partner Therapeutics, Inc.: A Massachusetts-based biopharmaceutical company innovating cancer treatments.
Founded
2017Partner Therapeutics, Inc.: A Massachusetts-based biopharmaceutical company innovating cancer treatments.
Partner Therapeutics, Inc., founded in Massachusetts, is a biopharmaceutical company dedicated to developing and commercializing innovative cancer treatments. Their core mission is to enhance the effectiveness of existing therapies and bring new solutions to market, particularly focusing on oncology. The company's flagship product, LEUKINE® (Sargramostim), is used to stimulate the immune system in cancer patients. Partner Therapeutics aims to address unmet medical needs and improve patient outcomes through rigorous scientific research and strategic partnerships.
Notable figures affiliated with Partner Therapeutics include experienced leaders in biopharmaceuticals and oncology. The company has garnered support from key investors who believe in its mission to revolutionize cancer treatment. Among its significant achievements is the successful commercialization of LEUKINE®, which has shown promise in various clinical trials, including applications related to COVID-19. Overall, Partner Therapeutics has made a substantial impact by advancing therapeutic options and improving the quality of life for cancer patients.
Companies similar to Partner Therapeutics include PanTher Therapeutics, Parthenon Therapeutics, Advanced Cancer Therapeutics and Tango Therapeutics.
Partner Therapeutics was founded in 2017.
Partner Therapeutics' headquarters is located in Lexington, MA, US.
Partner Therapeutics' most recent funding round was for $60M (USD) in February 2018.
As of Feb 1, 2018, Partner Therapeutics has raised a total of $60M (USD).
Partner Therapeutics has 227 employees as of Feb 5, 2024.
Advanced Cancer Therapeutics
